Esophageal Cancer TNM StagingNCT03635619
The Application of 3T MRI in Esophageal Cancer
An observational study of Esophageal Cancer TNM Staging and Magnetic Resonance Imaging, run by Henan Cancer Hospital at 1 site in China.
Trial summary
It is very significant that assessing TN staging in esophageal cancer patients before surgery, furthermore, determining the optimize surgical strategy, predict the the efficacy of radiotherapy for patients who were not chosen to be surgeried, and define the range of lymph node for radiotherapy. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Esophageal Cancer TNM Staging, Magnetic Resonance Imaging, Prognosis
- How many people
- 400 participants
- Where
- 1 siteChina
- Study dates
- 2 Sep 2018to 30 Dec 2023
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: subjects with endoscopically biopsy-proven EC will receive treatment.
Who may be able to join
- Consecutive patients with preoperative pathologically con-firmed EC by endoscopy and preoperative imaging data (esophagography\CT\EUS\MRI) were included.
- No contraindications for MRI examination.
- The patients participate in this study with informed consent.
Who cannot join
- The patients couldn't performed MR scanning or artefacts affect the evaluation.
- ThePatients are extremely anxious and uncooperative about surgery or neoadjuvant therapy.
- PatientsThe patients refuse to participate in the project.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Henan Cancer Hospital
Zhengzhou
Jinrong Qu, MD, qjryq@126.com
About this study
Official title: 3 T MRI in the Preoperative TN Staging and Prediction of Response to Neoadjuvant Therapy in Patients With Esophageal Cancer
It is very significant that assessing TN staging in esophageal cancer patients before surgery, furthermore, determining the optimize surgical strategy, predict the the efficacy of radiotherapy for patients who were not chosen to be surgeried, and define the range of lymph node for radiotherapy. It has been reported that the application of MRI in metastasis of lymph node of other cancer, but not in metastasis lymph node with esophageal cancer. Only a few studies focused on T staging using conventional MRI in esophageal cancer, however, relatively new sequences in the chest deserve widely used. To develop a pre-treatment evaluation methods for TN staging in patient with esophageal cancer by utilization of the new imaging methods (T2-TSE-BLADE, T2 maps, StarVIBE). By analysising the relationship between TN staging and imaging features to find the imaging characteristics for TN staging, and to find the indicators of magnetic resonance imaging new technology and reference values for facilitate pre-treatment diagnosis of lymphnode metastasis, optimize surgical strategy, predict the the efficacy of adjunctive therapy, and OS and define the range of lymph node for radiotherapy, as making personal treatment planning for esophageal cancer.
Read the detailed description
To explore the value of 3 T MRI using multiple sequences, including T2-TSE-BLADE, T2 maps and StarVIBE, in evaluating the preoperative TN staging and prediction of response to neoadjuvant therapy and OS in patients with esophageal cancer.
Patients with endoscopically biopsy-proven EC were prospectively enrolled for imaging on a 3 T scanner. The MRI protocol included T2-TSE-BLADE, T2 maps and StarVIBE sequences, and so on. Patients received treatment according to NCCN guideline. Readers assigned a TN stage on MRI, and post-operative pathologic confirmation was considered the gold standard. Inter-reader agreement, the diagnostic accuracy of TN staging on MRI were analyzed and compared to post-operative pathologic TN staging. MRI features were analyzed to find the correlation between pretreatment MRI features and response or OS. The study will includ 400 patients. Inter-reader agreements of TN staging were analyzed excellent for MRI. Diagnostic accuracy of MRI will be calculated.
- Being tested
- No intervention
- Keywords
- Esophageal Cancer, Magnetic Resonance Imaging, Prognosis, neoplasm staging
- Medical subject headings
- Esophageal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
No interventionOther
No intervention
What is being measured
The primary outcome is the main question the study is designed to answer.
MRI TN staging in Esophageal Cancer
To explore the value of 3 T MRI using multiple sequences in evaluating the preoperative TN staging of esophageal cancer treated with surgery, with pathologic confirmation
Measured: Sep 1, 2018-Dec 31, 2019
Secondary outcomes (1)
MRI prediction of prognosis in esophageal cancer
To explore the value of 3 T MRI using multiple sequences in predicting the response and OS of esophageal cancer treated with surgery.
Measured: Sep 1, 2018-Dec 31, 2020
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Aug 2018
- Study start2 Sep 2018
- Primary completion30 Dec 2023 (estimated)
- Study completion30 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for Esophageal Cancer TNM StagingStudies of the same condition, open and under way.
- More trials run by Henan Cancer HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Henan Cancer Hospital
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Baoxia He, MD, Study director, Henan Cancer Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03635619
- Sponsor's protocol ID
- FSK001
- Status last verified
- Aug 2019
- First submitted
- 15 Aug 2018
- Last updated
- 1 Apr 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Dumont P, Wihlm JM, Hentz JG, Roeslin N, Lion R, Morand G. Respiratory complications after surgical treatment of esophageal cancer. A study of 309 patients according to the type of resection. Eur J Cardiothorac Surg. 1995;9(10):539-43. doi: 10.1016/s1010-7940(05)80001-6.
PubMed 8562096Wu CC, Chen CJ. Esophageal carcinoma. N Engl J Med. 2015 Apr 9;372(15):1472. doi: 10.1056/NEJMc1500692. No abstract available.
PubMed 25853761Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, Ten Kate FJ, Obertop H, Tilanus HW, van Lanschot JJ. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007 Dec;246(6):992-1000; discussion 1000-1. doi: 10.1097/SLA.0b013e31815c4037.
PubMed 18043101Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, the British Society of Gastroenterology and the British Association of Surgical Oncology. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011 Nov;60(11):1449-72. doi: 10.1136/gut.2010.228254. Epub 2011 Jun 24. No abstract available.
PubMed 21705456Chen J, Chen C, Xia C, Huang Z, Zuo P, Stemmer A, Song B. Quantitative free-breathing dynamic contrast-enhanced MRI in hepatocellular carcinoma using gadoxetic acid: correlations with Ki67 proliferation status, histological grades, and microvascular density. Abdom Radiol (NY). 2018 Jun;43(6):1393-1403. doi: 10.1007/s00261-017-1320-3.
PubMed 28939963Cassinotto C, Feldis M, Vergniol J, Mouries A, Cochet H, Lapuyade B, Hocquelet A, Juanola E, Foucher J, Laurent F, De Ledinghen V. MR relaxometry in chronic liver diseases: Comparison of T1 mapping, T2 mapping, and diffusion-weighted imaging for assessing cirrhosis diagnosis and severity. Eur J Radiol. 2015 Aug;84(8):1459-1465. doi: 10.1016/j.ejrad.2015.05.019. Epub 2015 May 19.
PubMed 26032126Zhang H, Xue H, Alto S, Hui L, Kannengiesser S, Berthold K, Jin Z. Integrated Shimming Improves Lesion Detection in Whole-Body Diffusion-Weighted Examinations of Patients With Plasma Disorder at 3 T. Invest Radiol. 2016 May;51(5):297-305. doi: 10.1097/RLI.0000000000000238.
PubMed 26704452Li X, Qu JR, Luo JP, Li J, Zhang HK, Shao NN, Kwok K, Zhang SN, Li YL, Liu CC, Zee CS, Li HL. Effect of intravenous gadolinium-DTPA on diffusion-weighted imaging of brain tumors: a short temporal interval assessment. J Magn Reson Imaging. 2014 Sep;40(3):616-21. doi: 10.1002/jmri.24386. Epub 2013 Oct 31.
PubMed 24925118Zhang F, Qu J, Zhang H, Liu H, Qin J, Ding Z, Li Y, Ma J, Zhang Z, Wang Z, Zhang J, Zhang S, Dong Y, Grimm R, Kamel IR, Li H. Preoperative T Staging of Potentially Resectable Esophageal Cancer: A Comparison between Free-Breathing Radial VIBE and Breath-Hold Cartesian VIBE, with Histopathological Correlation. Transl Oncol. 2017 Jun;10(3):324-331. doi: 10.1016/j.tranon.2017.02.006. Epub 2017 Mar 19.
PubMed 28327459
Study at a glance
From the registry record, last updated by the sponsor on 1 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- 3 T MRI in the Preoperative TN Staging and Prediction of Response to Neoadjuvant Therapy in Patients With Esophageal Cancer
- ClinicalTrials.gov ID
- NCT03635619
- Acronym / sponsor ID
- FSK001
- Keywords
- Esophageal Cancer, Magnetic Resonance Imaging, Prognosis, neoplasm staging
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Henan Cancer HospitalOther government
- Study start
- 2 Sep 2018 (actual)
- Primary completion
- 30 Dec 2023 (estimated)
- Study completion
- 30 Dec 2023 (estimated)
- First posted
- 17 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
It is very significant that assessing TN staging in esophageal cancer patients before surgery, furthermore, determining the optimize surgical strategy, predict the the efficacy of radiotherapy for patients who were not chosen to be surgeried, and define the range of lymph node for radiotherapy. It has been reported that the application of MRI in metastasis of lymph node of other cancer, but not in metastasis lymph node with esophageal cancer. Only a few studies focused on T staging using conventional MRI in esophageal cancer, however, relatively new sequences in the chest deserve widely used. To develop a pre-treatment evaluation methods for TN staging in patient with esophageal cancer by utilization of the new imaging methods (T2-TSE-BLADE, T2 maps, StarVIBE). By analysising the relationship between TN staging and imaging features to find the imaging characteristics for TN staging, and to find the indicators of magnetic resonance imaging new technology and reference values for facilitate pre-treatment diagnosis of lymphnode metastasis, optimize surgical strategy, predict the the efficacy of adjunctive therapy, and OS and define the range of lymph node for radiotherapy, as making personal treatment planning for esophageal cancer.
Detailed description
To explore the value of 3 T MRI using multiple sequences, including T2-TSE-BLADE, T2 maps and StarVIBE, in evaluating the preoperative TN staging and prediction of response to neoadjuvant therapy and OS in patients with esophageal cancer.
Patients with endoscopically biopsy-proven EC were prospectively enrolled for imaging on a 3 T scanner. The MRI protocol included T2-TSE-BLADE, T2 maps and StarVIBE sequences, and so on. Patients received treatment according to NCCN guideline. Readers assigned a TN stage on MRI, and post-operative pathologic confirmation was considered the gold standard. Inter-reader agreement, the diagnostic accuracy of TN staging on MRI were analyzed and compared to post-operative pathologic TN staging. MRI features were analyzed to find the correlation between pretreatment MRI features and response or OS. The study will includ 400 patients. Inter-reader agreements of TN staging were analyzed excellent for MRI. Diagnostic accuracy of MRI will be calculated.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 5 Years
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- subjects with endoscopically biopsy-proven EC will receive treatment.
Key inclusion criteria (3 listed)
- Consecutive patients with preoperative pathologically con-firmed EC by endoscopy and preoperative imaging data (esophagography\CT\EUS\MRI) were included.
- No contraindications for MRI examination.
- The patients participate in this study with informed consent.
Key exclusion criteria (3 listed)
- The patients couldn't performed MR scanning or artefacts affect the evaluation.
- ThePatients are extremely anxious and uncooperative about surgery or neoadjuvant therapy.
- PatientsThe patients refuse to participate in the project.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| No interventionNo intervention | Other | – |
Primary outcome
MRI TN staging in Esophageal Cancer
Time frame: Sep 1, 2018-Dec 31, 2019
To explore the value of 3 T MRI using multiple sequences in evaluating the preoperative TN staging of esophageal cancer treated with surgery, with pathologic confirmation
1 secondary outcome
MRI prediction of prognosis in esophageal cancer
Time frame: Sep 1, 2018-Dec 31, 2020
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Apr 2020.
- Background: PubMed 8562096Dumont P, Wihlm JM, Hentz JG, Roeslin N, Lion R, Morand G. Respiratory complications after surgical treatment of esophageal cancer. A study of 309 patients according to the type of resection. Eur J Cardiothorac Surg. 1995;9(10):539-43. doi: 10.1016/s1010-7940(05)80001-6.
- Background: PubMed 25853761Wu CC, Chen CJ. Esophageal carcinoma. N Engl J Med. 2015 Apr 9;372(15):1472. doi: 10.1056/NEJMc1500692. No abstract available.
- Background: PubMed 18043101Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, Ten Kate FJ, Obertop H, Tilanus HW, van Lanschot JJ. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007 Dec;246(6):992-1000; discussion 1000-1. doi: 10.1097/SLA.0b013e31815c4037.
- Background: PubMed 21705456Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, the British Society of Gastroenterology and the British Association of Surgical Oncology. Guidelines for the management of oesophageal and gastric cancer. Gut. 2011 Nov;60(11):1449-72. doi: 10.1136/gut.2010.228254. Epub 2011 Jun 24. No abstract available.
- Background: PubMed 28939963Chen J, Chen C, Xia C, Huang Z, Zuo P, Stemmer A, Song B. Quantitative free-breathing dynamic contrast-enhanced MRI in hepatocellular carcinoma using gadoxetic acid: correlations with Ki67 proliferation status, histological grades, and microvascular density. Abdom Radiol (NY). 2018 Jun;43(6):1393-1403. doi: 10.1007/s00261-017-1320-3.
- Background: PubMed 26032126Cassinotto C, Feldis M, Vergniol J, Mouries A, Cochet H, Lapuyade B, Hocquelet A, Juanola E, Foucher J, Laurent F, De Ledinghen V. MR relaxometry in chronic liver diseases: Comparison of T1 mapping, T2 mapping, and diffusion-weighted imaging for assessing cirrhosis diagnosis and severity. Eur J Radiol. 2015 Aug;84(8):1459-1465. doi: 10.1016/j.ejrad.2015.05.019. Epub 2015 May 19.
- Background: PubMed 26704452Zhang H, Xue H, Alto S, Hui L, Kannengiesser S, Berthold K, Jin Z. Integrated Shimming Improves Lesion Detection in Whole-Body Diffusion-Weighted Examinations of Patients With Plasma Disorder at 3 T. Invest Radiol. 2016 May;51(5):297-305. doi: 10.1097/RLI.0000000000000238.
- Background: PubMed 24925118Li X, Qu JR, Luo JP, Li J, Zhang HK, Shao NN, Kwok K, Zhang SN, Li YL, Liu CC, Zee CS, Li HL. Effect of intravenous gadolinium-DTPA on diffusion-weighted imaging of brain tumors: a short temporal interval assessment. J Magn Reson Imaging. 2014 Sep;40(3):616-21. doi: 10.1002/jmri.24386. Epub 2013 Oct 31.
- Background: PubMed 28327459Zhang F, Qu J, Zhang H, Liu H, Qin J, Ding Z, Li Y, Ma J, Zhang Z, Wang Z, Zhang J, Zhang S, Dong Y, Grimm R, Kamel IR, Li H. Preoperative T Staging of Potentially Resectable Esophageal Cancer: A Comparison between Free-Breathing Radial VIBE and Breath-Hold Cartesian VIBE, with Histopathological Correlation. Transl Oncol. 2017 Jun;10(3):324-331. doi: 10.1016/j.tranon.2017.02.006. Epub 2017 Mar 19.
- Individual participant dataSharing planned: Undecided
Related trials for Esophageal Cancer TNM Staging
RecruitingPhase 1/2
Establishing Best Treatment Strategy for T4 Esophageal Cancer
Esophageal Cancer TNM Staging Primary Tumor (T) T4
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Baoxia He, MD study director
Henan Cancer Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Esophageal Cancer TNM Staging and Magnetic Resonance Imaging, run by Henan Cancer Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Jinrong Qu (0371-65587595, qjryq@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MRI TN staging in Esophageal Cancer (time frame: Sep 1, 2018-Dec 31, 2019). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03635619, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2020.